Selective Protein Tyrosine Phosphatase 1B Inhibitors: Targeting the Second Phosphotyrosine Binding Site with Non-Carboxylic Acid-Containing Ligands.
Liu, G., Xin, Z., Liang, H., Abad-Zapatero, C., Hajduk, P.J., Janowick, D.A., Szczepankiewicz, B.G., Pei, Z., Hutchins, C.W., Ballaron, S.J., Stashko, M.A., Lubben, T.H., Berg, C.E., Rondinone, C.M., Trevillyan, J.M., Jirousek, M.R.(2003) J Med Chem 46: 3437-3440
- PubMed: 12877578 
- DOI: https://doi.org/10.1021/jm034088d
- Primary Citation of Related Structures:  
1PH0 - PubMed Abstract: 
Protein tyrosine phosphatase (PTPase) 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling cascades. We identified several salicylic acid-based ligands for the second phosphotyrosine binding site of PTP1B using a NMR-based screening. Structure-based linking with a catalytic site-directed oxalylarylaminobenzoic acid-based pharmacophore led to the identification of a novel series of potent PTP1B inhibitors exhibiting 6-fold selectivity over the highly homologous T-cell PTPase (TCPTP) and high selectivity over other phosphatases.
Organizational Affiliation: 
Metabolic Disease Research and Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6098, USA. gang.liu@abbott.com